WallStreetZenWallStreetZen

NASDAQ: KPRX
Kiora Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for KPRX

Based on 3 analysts offering 12 month price targets for Kiora Pharmaceuticals Inc.
Min Forecast
$2.50-67.32%
Avg Forecast
$3.83-49.9%
Max Forecast
$6.50-15.03%

Should I buy or sell KPRX stock?

Based on 4 analysts offering ratings for Kiora Pharmaceuticals Inc.
Strong Buy
Strong Buy
2 analysts 50%
Buy
1 analysts 25%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their KPRX stock forecasts and price targets.

KPRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Ladenburg Thalmann
Bottom 22%
22
Strong BuyInitiates Coverage On$6.50-15.03%2022-08-25
Maxim Group
Bottom 15%
15
HoldDowngradesN/AN/A2022-08-15
HC Wainwright & Co.
Top 5%
96
BuyMaintains$2.50-67.32%2022-07-11
Maxim Group
Bottom 2%
2
Strong BuyInitiates Coverage On$2.50-67.32%2022-01-19

1 of 1

Forecast return on equity

Is KPRX forecast to generate an efficient return?
Company
-2.94%
Industry
22.46%
Market
122.06%
KPRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KPRX forecast to generate an efficient return on assets?
Company
-1.66%
Industry
13.57%
KPRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KPRX earnings per share forecast

What is KPRX's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.48
Avg 2 year Forecast
-$0.04
Avg 3 year Forecast
-$0.30

KPRX revenue forecast

What is KPRX's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$8.3M
Avg 2 year Forecast
$200.0k
Avg 3 year Forecast
$1.3M

KPRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KPRX$7.65$3.83-49.90%Strong Buy
CFRX$0.18$3.00+1,566.67%Buy
SONN$1.64$2.00+21.95%Strong Buy
CNSP$0.18$10.00+5,394.51%Buy
ENVB$4.64$0.73-84.38%Buy

Kiora Pharmaceuticals Stock Forecast FAQ

Is Kiora Pharmaceuticals Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: KPRX) stock is to Strong Buy KPRX stock.

Out of 4 analysts, 2 (50%) are recommending KPRX as a Strong Buy, 1 (25%) are recommending KPRX as a Buy, 1 (25%) are recommending KPRX as a Hold, 0 (0%) are recommending KPRX as a Sell, and 0 (0%) are recommending KPRX as a Strong Sell.

If you're new to stock investing, here's how to buy Kiora Pharmaceuticals stock.

What is KPRX's earnings growth forecast for 2022-2024?

(NASDAQ: KPRX) Kiora Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.86%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.88%.

Kiora Pharmaceuticals's earnings in 2022 is -$14,686,391.On average, 3 Wall Street analysts forecast KPRX's earnings for 2022 to be -$441,157, with the lowest KPRX earnings forecast at -$523,874, and the highest KPRX earnings forecast at -$395,204. On average, 3 Wall Street analysts forecast KPRX's earnings for 2023 to be -$36,763, with the lowest KPRX earnings forecast at -$275,723, and the highest KPRX earnings forecast at $321,677.

In 2024, KPRX is forecast to generate -$275,723 in earnings, with the lowest earnings forecast at -$275,723 and the highest earnings forecast at -$275,723.

What is KPRX's revenue growth forecast for 2022-2027?

(NASDAQ: KPRX) Kiora Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 23.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.53%.

Kiora Pharmaceuticals's revenue in 2022 is $0.On average, 1 Wall Street analysts forecast KPRX's revenue for 2022 to be $7,628,347, with the lowest KPRX revenue forecast at $7,628,347, and the highest KPRX revenue forecast at $7,628,347. On average, 1 Wall Street analysts forecast KPRX's revenue for 2026 to be $183,816, with the lowest KPRX revenue forecast at $183,816, and the highest KPRX revenue forecast at $183,816.

In 2027, KPRX is forecast to generate $1,194,801 in revenue, with the lowest revenue forecast at $1,194,801 and the highest revenue forecast at $1,194,801.

What is KPRX's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: KPRX) forecast ROA is -1.66%, which is lower than the forecast US Biotechnology industry average of 13.57%.

What is KPRX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year KPRX price target, the average KPRX price target is $3.83, with the highest KPRX stock price forecast at $6.50 and the lowest KPRX stock price forecast at $2.50.

On average, Wall Street analysts predict that Kiora Pharmaceuticals's share price could fall to $3.83 by Aug 25, 2023. The average Kiora Pharmaceuticals stock price prediction forecasts a potential downside of 49.9% from the current KPRX share price of $7.65.

What is KPRX's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: KPRX) Kiora Pharmaceuticals's current Earnings Per Share (EPS) is -$47.20. On average, analysts forecast that KPRX's EPS will be -$0.48 for 2022, with the lowest EPS forecast at -$0.57, and the highest EPS forecast at -$0.43. On average, analysts forecast that KPRX's EPS will be -$0.04 for 2023, with the lowest EPS forecast at -$0.30, and the highest EPS forecast at $0.35. In 2024, KPRX's EPS is forecast to hit -$0.30 (min: -$0.30, max: -$0.30).

What is KPRX's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: KPRX) forecast ROE is -2.94%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.